India shipped over Rs.1,349bn worth drugs to over 200 markets in 2021
The Indian Pharmaceutical exports market grew by 11.88% between FY 2019 and FY 2022 to reach Rs.1,445.81 billion in FY 2022, despite the global pharmaceutical industry shrinking by 1-2% in 2020 due to COVID-19. This was despite the global industry output reduced by almost 2% in 2020 on account of COVID-19, said the “Pharmaceutical Export Market in India” report from ResearchAndMarkets.
The pharmaceutical industry has witnessed rapid growth in the past few decades and is expected to develop further, owing to huge export possibilities.
The business caters to 50% of the global demand of various vaccines, 40% of generic medicines demand in the US, and 25% of all medication in the UK, according to the report.
The onslaught of COVID-19 and the nationwide lockdown severely impacted the healthcare and pharmaceutical infrastructure, and the country’s economy. Travel restrictions, shortage of workforce, disruption in world trade, and bottleneck in logistics impacted the supply chain of pharmaceutical products, the report said on 5 May 2023.
During the second wave, key market players took major steps as per regulatory guidelines with smart solutions to tackle the supply-demand gap. As of 2021, India shipped over Rs.1,349 billion worth drugs to over 200 nations, ranging from the highly regulated markets in North America and Europe to countries with small pharmaceutical markets.
Major players such as Sun Pharmaceuticals Industries Limited, Aurobindo Pharma Limited, Lupin Limited and Dr. Reddy’s Laboratories Limited have made huge strides in their net revenue. This is because of government initiatives that propelled export possibilities.
Competitive landscape: Alkem Laboratories Limited, Aurobindo Pharma Limited, Cipla Limited, Divi’s Laboratories Limited, Dr. Reddy’s Laboratories Limited, Glenmark Pharmaceuticals Limited, Lupin Limited, Sun Pharmaceutical Industries Limited, Torrent Pharmaceuticals Limited and Zydus Lifesciences Limited. fiinews.com
